Systemic Sclerosis and Jak Inhibitors : Emphasis on Macrophages

Systemic Sclerosis Clinical Trial

— SCLERO JAK  

Official title:

Systemic Sclerosis and Jak Inhibitors : Emphasis on Macrophages

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04206644
• Other study ID #: 35RC19_30043_SCLERO JAK
• Status: Active, not recruiting
• Start date: January 21, 2021
• Est. completion date: February 13, 2027

Study information

• Verified date: April 2023
• Source: Rennes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The Sclero-JAK project aims to assess the impact of a JAK1/2 inhibitor (ruxolitinib) on activation states of monocytes-derived macrophages (MDM) from systemic sclerosis (SSc) patients

Description:

Systemic sclerosis is a fibrotic and inflammatory chronic autoimmune disorder with no disease modifiying drug available to date. JAK inhibitors may represent a relevant therapeutic candidate for this disease;

The primary objective of this study is to characterize the impact of Ruxolitinib (a JAK ½ inhibitor) on the prof-fibrotic properties of MDM from SSc patients in vitro.

The primary outcome will be the concentration of CCL18 evaluate by ELISA in the condition media of MDM from SSc patients pre treated or not in vitro by ruxolitinib.

The secondary objectives :

1. To characterize the impact of ruxolitinib on other pro-inflammatory or pro-fibrotic cytokines

2. To characterize the impact of ruxolitinib on membrane expression of macrophagic polarization markers of MDM from SSc patients

3. To evaluate the impact of ruxolitinib on the phenotype of MDM from healthy donors exposed in vitro to the serum of SSc patients.

4. To determine the variability of the effects of ruxolitinib on MDM of SSc patients depending on key clinical characteristics (diffuse versus limited SSc, patients with or without Interstitial Lung disease ILD)

The secondary outcomes :

1. ELISA of the following cytokine evaluated in the condition media of SSc MDM pre-treated or not with ruxolitinib : PDGFbb, IL-6, CXCL10, CXCL4

2. Membrane expression (flow cytometry) of the following markers expressed by SSc MDM pre-treated or not with ruxoltinib : CD204, CD206, CD163, CD86, CMHII, TLR4.

3. Evaluation of the same cytokines and membrane markers in MDM from HD exposed to serum media of SSc patients.

4. Variation of the effect of ruxolitinib on the primary outcome (CCL18 secreted in the condition media of MDM from SSc patients) in sub groups depending on the following characteristics :

• Auto antibodies (anticentromere, antitopoisomerase, anti RNA polymerase III or none)

• modified Rodnan skin score

• Digital ulcers (current or past)

• Pulmonary involvement (Interstitial Lung disease on CT scan)

• Heart involvement (Pulmonary arterial hypertension on echocardiography)

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 150
• Est. completion date: February 13, 2027
• Est. primary completion date: January 13, 2023
• Gender: All
• Age group: 18 Years to 18 Years

Eligibility

Inclusion Criteria:

• patients with systemic sclerosis according to the ACR/EULAR 2013 classification criteria for systemic sclerosis or Patients with systemic lupus according to the ACR2019 classification criteria for systemic lupus

• with informed consent for participation to the study

Exclusion Criteria:

• patients unable to consent

• patients with anemia inferior to 7g/dL

Related Conditions & MeSH terms

• Scleroderma, Diffuse
• Scleroderma, Systemic
• Sclerosis
• Systemic Sclerosis

Intervention

Other:
• biological analysis
biological analysis of the Concentration of CCL18

Locations

Country	Name	City	State
France	Rennes University Hospital	Rennes

Sponsors (1)

Lead Sponsor	Collaborator
Rennes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concentration of CCL18 in the condition media of MDM from SSc patients	at the end of the study	through study completion, an average of 4 year